PF 5089771

Drug Profile

PF 5089771

Alternative Names: PF-05089771; PF-5089771

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Icagen
  • Developer Icagen, Inc.; XRpro Sciences
  • Class Analgesics; Small molecules
  • Mechanism of Action Nav1.7-voltage-gated-sodium-channel-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Neuropathic pain; Pain
  • Discontinued Dental pain

Most Recent Events

  • 01 Mar 2015 Pfizer completes a phase I trial in Healthy volunteers in the Netherlands (PO) (NCT02349607)
  • 23 Jan 2015 Pfizer plans a phase I trial for Pain (In volunteers) in the Netherlands (NCT02349607)
  • 01 Jan 2015 Phase-I clinical trials in Pain (in volunteers) in Netherlands (PO) (NCT02349607, EudraCT2014-004468-39)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top